Skip to main content
  • FDA approval and commercial launch of Joenja® (leniolisib) in the U.S.

  • Joenja® launch off to strong start with 23 U.S. patients on paid therapy

  • Revenues decreased by 9% to US$42.5 million, compared to the first quarter of 2022, primarily due to temporary reimbursement disruptions for some patients on government insurance programs. This issue, affecting all of the HAE market, has since resolved

  • Continue to anticipate low single digit growth in annual revenues from RUCONEST® in 2023

  • Continued significant investments made in leniolisib launch preparations and organizational structure

  • Overall cash balance of US$184.8 million at the end of the quarter

Pharming hosted a presentation for analysts and investors at 13:30 CET/07:30 EDT on May 11, 2023 (rewatch webcast). Download the presentation slides and the transcript below.

"The launch of Joenja® is off to a strong start and Pharming is one step closer to its goal of becoming a leading global rare disease company dedicated to patient communities with unmet medical needs."

- Sijmen de Vries, MD | Chief Executive Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline